aflibercept-ayyh (Pavblu) vs Ranibizumab (Ximluci)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
aflibercept-ayyh (Pavblu)
Marketed by Amgen
NCT04270747 · Phase 3 · completed
This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.
Reported efficacy
Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)
Result source: NCT04270747
Ranibizumab (Ximluci)
Marketed by STADA Arzneimittel and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Age-Related Macular Degeneration
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. aflibercept-ayyh (Pavblu): 5 of 5 rows · Ranibizumab (Ximluci): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | aflibercept-ayyh (Pavblu) | Ranibizumab (Ximluci) |
|---|---|---|
| BCVA Change Letters absolute change · Letters | 6.4 vs 6.5 Aflibercept Letters @ 8wka,b,c NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 1 more dose6.5 vs 7.6 Aflibercept Letters @ 8wk NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 4.57 vs 6.37 Lucentis Letters @ 8wkb,c NCT03805100 · Phase 3 |
| Dropout rate | 5.2%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 16.1%d NCT03805100 · Phase 3 |
| Discontinued due to AEs | 0.3%ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results—Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | —d NCT03805100 · Phase 3 |
| Serious AEs | —ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 2 more results8.1%Post Week 16: ABP 938 / ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.1%Through Week 16: ABP 938 NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 | 11.3%d NCT03805100 · Phase 3 |
| Most frequent reported AEs | neovascular age-related macular degeneration 5.9% conjunctival haemorrhage 1.5% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 1 more resultconjunctival haemorrhage 4.2% neovascular age-related macular degeneration 2.1% NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
aflibercept-ayyh (Pavblu)
show 3 more results
show 7 more results
Ranibizumab (Ximluci)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-ayyh (Pavblu)'s landscape · Ranibizumab (Ximluci)'s landscape